GSK-3 Beta (3A6) Monoclonal Antibody, Cy3 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-33293M-Cy3-100uL |
| Product Name | GSK-3 Beta (3A6) Monoclonal Antibody, Cy3 Conjugated |
| Applications |
WB
IF
|
| Specificity | KO-Validated |
| Reactivity | Human, Mouse, Rat, Dog |
| Specifications | |
| Conjugation | Cy3 |
| Host | Mouse |
| Source | KLH conjugated synthetic peptide derived from human GSK-3 Beta |
| Clonality | Monoclonal |
| Clone # | 3A6 |
| Isotype | IgG |
| Concentration | Lot Dependent |
| Purification | Purified by Protein G. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 2932 |
| Swiss Prot | P49841 |
| Subcellular location | Cytoplasm, Nucleus, Cell membrane |
| Synonyms | Glycogen synthase kinase-3 beta; GSK3B; GSK-3 beta; Serine/threonine-protein kinase GSK3B |
| Background | Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). |
| Application Dilution | |
| WB | 1:300-5000 |
| IF | 1:50-200 |
Frequently asked questions
Which applications is GSK-3 Beta (3A6) Monoclonal Antibody, Cy3 Conjugated (bsm-33293M-Cy3) validated for, and at what dilution?
bsm-33293M-Cy3 is validated for WB (1:300-5000); IF (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does GSK-3 Beta (3A6) Monoclonal Antibody, Cy3 Conjugated (bsm-33293M-Cy3) react with?
Tested reactivity: Human, Mouse, Rat, Dog.
How should bsm-33293M-Cy3 be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise GSK-3 Beta (3A6) Monoclonal Antibody, Cy3 Conjugated (bsm-33293M-Cy3)?
KLH conjugated synthetic peptide derived from human GSK-3 Beta
What are the excitation and emission wavelengths of the Cy3 conjugate (bsm-33293M-Cy3)?
Cy3 on bsm-33293M-Cy3: excitation / emission 512,550nm/570,615nm.